Peritoneal Mesothelioma | Abdominal Cancer, Symptoms & Treatment (HIPEC)

What is Peritoneal Mesothelioma?

Peritoneal mesothelioma is a malignant cancer that develops in the peritoneum, the thin layer of tissue that lines the abdominal cavity and covers most of the organs within the abdomen. It accounts for approximately 15-20% of all mesothelioma cases, making it the second most common form after pleural mesothelioma.

The Peritoneum

The peritoneum serves several important functions:

Protection: Shields abdominal organs from infection and injury
Lubrication: Produces fluid allowing organs to move smoothly
Support: Holds organs in position within the abdomen
Immune function: Helps fight abdominal infections

How It Develops

Peritoneal mesothelioma develops when asbestos fibers become trapped in the peritoneum, causing chronic inflammation and cellular damage over decades. The cancer typically forms multiple small tumors across the abdominal lining rather than a single large mass.

Key Differences from Pleural Mesothelioma

Factor	Peritoneal	Pleural
Frequency	15-20% of cases	75% of cases
Median Survival	50+ months (with CRS/HIPEC)	12-21 months
Primary Treatment	CRS + HIPEC	Surgery + chemo
Symptoms	Abdominal	Respiratory

Peritoneal Mesothelioma Symptoms

Symptoms of peritoneal mesothelioma primarily affect the digestive system and abdominal region. Early symptoms are often vague and may be mistaken for other, less serious conditions.

Common Symptoms

Abdominal pain: Persistent discomfort, cramping, or aching in the stomach area
Abdominal swelling/distension: Noticeable increase in waist size due to fluid (ascites) or tumor growth
Early satiety: Feeling full after eating only small amounts
Loss of appetite: Decreased interest in food
Unexplained weight loss: Significant weight reduction without trying
Nausea and vomiting: Digestive upset that may worsen after meals

Secondary Symptoms

Changes in bowel habits (constipation or diarrhea)
Fatigue and weakness
Fever and night sweats
Anemia
Hernias (in some cases)
Fluid accumulation (ascites)

Symptom Progression

Symptoms typically develop gradually over weeks to months. As the cancer progresses:

Abdominal swelling becomes more pronounced
Pain may increase in severity
Digestive problems worsen
Weight loss accelerates
Bowel obstruction may occur

When to See a Doctor

Seek medical evaluation if you experience:

Persistent abdominal pain lasting more than 2-3 weeks
Unexplained abdominal swelling
Significant unintended weight loss
Changes in bowel habits
Early satiety combined with a history of asbestos exposure

Causes and Risk Factors

Like other forms of mesothelioma, peritoneal mesothelioma is primarily caused by asbestos exposure, though the pathway differs from pleural mesothelioma.

How Asbestos Causes Peritoneal Mesothelioma

Several mechanisms may explain how asbestos fibers reach the peritoneum:

Ingestion: Swallowed asbestos fibers penetrate the intestinal wall
Lymphatic transport: Inhaled fibers travel through lymphatic system to abdomen
Direct migration: Fibers migrate from pleural cavity through diaphragm
Blood circulation: Fibers circulate through bloodstream to abdominal organs

Latency Period

Peritoneal mesothelioma typically develops 20-40 years after asbestos exposure, though cases have been reported with shorter and longer latency periods.

High-Risk Groups

Workers with heavy occupational asbestos exposure
Those with combined inhalation and ingestion exposure
Secondary exposure victims (family members)
Individuals with prolonged environmental exposure

Gender Differences

Peritoneal mesothelioma occurs more frequently in women than pleural mesothelioma does. This may be due to:

Higher rates of secondary exposure in women (laundry of work clothes)
Different patterns of fiber transport
Potential hormonal factors

Diagnosing Peritoneal Mesothelioma

Accurate diagnosis of peritoneal mesothelioma requires a combination of imaging studies, fluid analysis, and surgical biopsy.

Imaging Studies

CT Scan (Primary Tool):

Detects tumor masses and thickening of peritoneum
Identifies ascites (fluid accumulation)
Assesses organ involvement
Helps stage the cancer
Guides biopsy procedures

MRI:

Provides detailed soft tissue imaging
Better assessment of tumor extent
Useful for surgical planning

PET Scan:

Identifies metastatic disease
Helps determine if cancer has spread beyond abdomen

Fluid Analysis

Paracentesis:

Removes ascitic fluid for analysis
Cytology may identify cancer cells
Relieves abdominal pressure

The paracentesis procedure is often used both diagnostically and therapeutically to manage fluid accumulation in peritoneal mesothelioma patients.

Biopsy

Laparoscopy (Preferred Method):

Minimally invasive surgical procedure
Direct visualization of abdominal cavity
Multiple tissue samples obtained
Assessment of surgical resectability

Laparoscopy allows surgeons to directly visualize the peritoneal lining, obtain diagnostic samples, and determine whether a patient is a candidate for peritoneal mesothelioma surgery.

Differential Diagnosis

Peritoneal mesothelioma must be distinguished from:

Ovarian cancer (in women)
Colorectal cancer
Peritoneal carcinomatosis from other cancers
Benign peritoneal conditions
Tuberculosis peritonitis

Peritoneal Mesothelioma Treatment Options

Treatment for peritoneal mesothelioma has advanced significantly, with cytoreductive surgery combined with HIPEC offering the best outcomes for eligible patients.

Cytoreductive Surgery (CRS)

The primary surgical treatment involves removing all visible tumors from the abdominal cavity:

Removal of tumor nodules from peritoneum
Resection of involved organs when necessary
Stripping of peritoneal lining
Omentectomy (removal of omentum)
May include removal of portions of stomach, intestines, liver, or spleen

Complete cytoreduction (removing all visible disease) is essential for optimal outcomes.

HIPEC (Heated Intraperitoneal Chemotherapy)

Delivered immediately after surgery while patient is still in operating room:

Chemotherapy heated to 104-107°F (40-42°C)
Circulated throughout abdominal cavity for 60-120 minutes
Heat increases chemotherapy effectiveness
Kills remaining microscopic cancer cells
High concentrations possible with limited systemic side effects

Intraperitoneal chemotherapy is a critical component of multimodal treatment, allowing physicians to deliver chemotherapy directly to the abdominal cavity where tumors are located.

Systemic Chemotherapy

For patients not eligible for surgery:

Pemetrexed and cisplatin combination
Carboplatin may substitute for cisplatin
Gemcitabine-based regimens
Clinical trial options

Palliative Treatments

For symptom management:

Paracentesis to relieve fluid buildup
PleurX catheter for recurrent ascites
Pain management
Nutritional support

The CRS/HIPEC Procedure

CRS combined with HIPEC has revolutionized peritoneal mesothelioma treatment, dramatically improving survival compared to historical outcomes.

Who Qualifies for CRS/HIPEC

Ideal candidates typically have:

Epithelioid cell type
Limited tumor burden (PCI score typically under 20)
Good overall health and organ function
No metastasis outside abdominal cavity
Able to tolerate major surgery

The Surgical Procedure

Exploration: Surgeon assesses extent of disease
Tumor removal: All visible tumors excised
Peritonectomy: Diseased peritoneal lining removed
Organ resection: Removal of involved organs if necessary
HIPEC delivery: Heated chemotherapy circulated
Reconstruction: Restoration of gastrointestinal continuity

Recovery

Hospital stay: 7-14 days typical
Recovery period: 6-12 weeks
Nutritional support often required
Close monitoring for complications

Risks and Complications

Infection
Bleeding
Bowel obstruction or leak
Blood clots
Kidney problems
Nutritional deficiencies

Mortality rate is typically 2-5% in experienced centers.

Peritoneal Mesothelioma Prognosis

Peritoneal mesothelioma generally has a better prognosis than pleural mesothelioma, particularly for patients who receive CRS/HIPEC treatment.

Survival Statistics

Treatment	Median Survival	5-Year Survival
CRS + HIPEC	50+ months	30-50%
Systemic chemo only	12-24 months	<10%
No treatment	6-12 months	<5%

Factors Affecting Prognosis

Completeness of cytoreduction: Complete removal of visible disease is critical
PCI score: Lower peritoneal cancer index indicates better prognosis
Cell type: Epithelioid has best outcomes; biphasic and sarcomatoid poorer
Lymph node involvement: Node-negative patients do better
Response to HIPEC: Complete response improves survival

Long-Term Survivors

A significant percentage of patients treated with CRS/HIPEC achieve long-term survival:

Some patients survive 5-10+ years
Complete remission possible in select cases
Quality of life often good in survivors

Frequently Asked Questions

Is peritoneal mesothelioma curable?

While not typically considered curable, peritoneal mesothelioma can be controlled for extended periods, and some patients achieve long-term survival. CRS/HIPEC treatment has produced 5-year survival rates of 30-50% and some patients live 10+ years. The term "cure" is rarely used, but long-term remission is possible.

How is peritoneal mesothelioma different from ovarian cancer?

Both can cause abdominal symptoms and ascites, but they are distinct cancers. Peritoneal mesothelioma affects the peritoneal lining, while ovarian cancer originates in the ovaries. Pathology examination distinguishes them—mesothelioma cells differ microscopically from ovarian cancer cells. Immunohistochemistry staining helps confirm the diagnosis.

What is the PCI score?

The Peritoneal Cancer Index (PCI) is a scoring system that assesses the extent of cancer spread in the abdomen. The abdomen is divided into 13 regions, each scored 0-3 based on tumor size. Total scores range from 0-39. Lower scores (typically under 20) indicate limited disease and better candidates for CRS/HIPEC.

Is HIPEC painful?

HIPEC is performed while the patient is under general anesthesia, so the procedure itself is not painful. Post-operative discomfort is managed with pain medication. Recovery from CRS/HIPEC is significant surgery, and patients should expect several weeks of recovery with fatigue and some discomfort.

Can peritoneal mesothelioma spread to other organs?

Yes, peritoneal mesothelioma can spread (metastasize) to other abdominal organs including the liver, spleen, and intestines. It can also spread outside the abdomen to distant sites, though this is less common than with pleural mesothelioma. Advanced imaging helps determine the extent of spread.

Where should I go for CRS/HIPEC treatment?

CRS/HIPEC should only be performed at specialized centers with extensive experience. Major cancer centers with established HIPEC programs include: Wake Forest Baptist Medical Center, Washington Cancer Institute, University of Pittsburgh Medical Center, and several others. Experience matters significantly for outcomes.

Find a CRS/HIPEC Specialist

Not all cancer centers offer CRS/HIPEC treatment. Get help finding experienced peritoneal mesothelioma specialists and treatment centers near you.

Connect with Specialists